For this week's Article of the Week relates to a presentation made by Petere Croucher on the osteocyte-specific protein sclerostin at the most...
Myeloma NZ
Article of the week: Letters to Blood – Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
GarcÃa-Guerrero et al described their laboratory study where myeloma cells from 12 patients were treated with titrated doses of panobinostat (0, 10...
Expert Forum: Myeloma Summit August 2016
This publication is a summary of selected presentations delivered at the Haematology Society of Australia and New Zealand (HSANZ) Inaugural...
Newsletter: July 2017
Welcome to the first newsletter from Myeloma New Zealand. Setting up a new entity from scratch was always going to take time but we have made...
Research Review: Multiple Myeloma – Issue 22
Issue 22 of Multiple Myeloma Research Review. Highlights include: •  Benefits of low dose lenalidomide in relapsed/refractory MM. •  Network...
Article of the week: Phase 1b study of isatuximab plus lenalidomide and dexamethasone
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma'Â is a study intended to assess the...
Article of the week: The role of serum IgM levels as a predictor of symptomatic hyperviscosity in Waldenström’s macroglobulinaemia (WM)
This week's Article of the Week is a study that was recently published in the British Journal of Haematology on the role of serum IgM levels as a...
Research Review: Research paper from the British Journal of Haematology
This latest report is a study published in the British Journal of Haematology comparing whole-body ultra-low dose CT (WBULDCT) with spinal MRI...
Drugs for incurable blood cancer ‘should be available’
About 400 New Zealanders a year are diagnosed with the blood cancer multiple myeloma, and the number is rising. A malignancy of the plasma cell, it...
Article of the week: Monoclonal antibody therapy in multiple myeloma
This review discusses pre-clinical and clinical studies on the use of monoclonal antibodies in multiple myeloma, including agents which have been...
Launch
On November 22, Â 2016 Â in Wellington a group of New Zealand based hematology specialists led by Kenneth Romeril launched a new initiative for...